Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Procalcitonin-An Enigmatic Anxiolytic Biomarker.

JAMA network open·2026
Same author

Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2026
Same author

Characterizing the in vitro and in vivo effect of bicarbonate on azithromycin activity against Acinetobacter baumannii.

PloS one·2026
Same author

Universal high-dose meropenem for antimicrobial-resistant Gram-negative infections: evidence or overreach?

European journal of hospital pharmacy : science and practice·2026
Same author

Evidence Over Eminence: Rethinking Specialty Guidelines Amid the ATS-IDSA Debate.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

A Once-in-a-Generation Transformation at an Academic Public Hospital During Federal Funding Uncertainty.

Journal of healthcare leadership·2026
Same journal

Anticalcitonin: Limited utility of a context-dependent biomarker demonstrated in another real-world data set.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Procalcitonin Testing in Community-Acquired Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Wanted: A Relevant Correlate of Protection for Dengue Vaccines.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Safety and Immunogenicity of the Live-Attenuated Quadrivalent Dengue Vaccine V181 Compared With Butantan-DV Among Healthy Adults in Brazil: A Randomized, Double-Blind, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Low Post-Treatment Recurrence After a Shortened All-oral Regimen for Pulmonary Rifampicin- or Multidrug-Resistant Tuberculosis in Individuals without Prior Second-Line Drug Exposure in Kazakhstan.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same journal

Sepsis Diagnostic Excellence and its Association with Mortality in Adults with Potential Infection.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
See all related articles

Related Experiment Video

Updated: May 26, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

Progress toward a Staphylococcus aureus vaccine.

Robert S Daum1, Brad Spellberg

  • 1Department of Pediatrics, Section of Infectious Diseases, The University of Chicago Medical Center, Chicago, IL, USA. rdaum@peds.bsd.uchicago.edu

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|December 22, 2011
PubMed
Summary
This summary is machine-generated.

Developing a Staphylococcus aureus (S. aureus) vaccine is urgent due to high infection rates and antibiotic resistance. Current vaccine strategies using single or multiple antigens have failed, highlighting the need for novel approaches.

More Related Videos

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
09:15

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection

Published on: February 28, 2019

Related Experiment Videos

Last Updated: May 26, 2026

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
08:32

Development and Assessment of Intracellular Infection Models for Staphylococcus aureus

Published on: January 17, 2025

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
07:32

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

Published on: September 1, 2023

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection
09:15

A Mouse Model to Assess Innate Immune Response to Staphylococcus aureus Infection

Published on: February 28, 2019

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Staphylococcus aureus infections present significant public health challenges, including invasive diseases, pneumonia, and skin infections.
  • The emergence of antibiotic resistance in S. aureus necessitates the urgent development of effective vaccines.
  • Previous vaccine candidates targeting capsular polysaccharides, isdB, clumping factor A, and lipoteichoic acid have been unsuccessful in clinical trials.

Purpose of the Study:

  • To review the challenges and potential strategies for developing a successful Staphylococcus aureus vaccine.
  • To explore alternative vaccine approaches beyond traditional opsonophagocytic antibodies.

Main Methods:

  • Review of existing literature on S. aureus pathogenesis and vaccine development efforts.
  • Analysis of previously failed vaccine clinical trial data.
  • Discussion of novel immunologic targets and strategies.

Main Results:

  • No single vaccine has proven effective against all S. aureus disease syndromes.
  • Current vaccine formulations utilizing single or multiple antigens have not met success.
  • Alternative strategies, including targeting staphylococcal protein A and T-helper 17 lymphocyte pathways, are under investigation.

Conclusions:

  • A successful S. aureus vaccine may require a combination of multiple antigens or novel immunologic mechanisms.
  • Further research is needed to identify optimal vaccine compositions and deployment strategies.
  • The development of a broadly protective S. aureus vaccine remains a critical unmet medical need.